The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the ...

The goal of hyperphosphatemia treatment should be to reduce serum phosphorus to ?5.5mg/dL (or closer to normal levels) and alleviate negative clinical outcomes for patients with CKD, including ...

About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD).

Treatment for Hyperphosphatemia to Generate a Value Pool exceeding US$ 20 Billion by 2033; Iron-based Phosphate Binders to account for 20% of Total Demand. Market share for hyperphosphatemia in ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

In this video, Kevin Martin, MD, discusses new and emerging technologies in the field of hyperphosphatemia.

Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to ...

RELATED: Keryx Submits NDA for Hyperphosphatemia Drug, Zerenex Ferric Citrate is also being developed as a treatment for iron deficiency anemia in patients with Stage 3– 5 non-dialysis dependent ...

Among the 184 survivors of 24-hour CRRT, hyperphosphatemia was associated with a significant 2.2 times and 2.6 times increased risk of death at 28 days and 90 days, respectively.

Among these patients, 76% have hyperphosphatemia, and the rate of achieving target phosphate levels is only 39% 1 (according to China’s hemodialysis quality control standards: serum phosphate 1. ...